GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio Vitos Pharma AB (OSTO:BIOVIT) » Definitions » Debt-to-Revenue

Bio Vitos Pharma AB (OSTO:BIOVIT) Debt-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Bio Vitos Pharma AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Bio Vitos Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Bio Vitos Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Bio Vitos Pharma AB's annualized Revenue for the quarter that ended in Dec. 2023 was kr3.28 Mil. Bio Vitos Pharma AB's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


Bio Vitos Pharma AB Debt-to-Revenue Historical Data

The historical data trend for Bio Vitos Pharma AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio Vitos Pharma AB Debt-to-Revenue Chart

Bio Vitos Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A - - - -

Bio Vitos Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bio Vitos Pharma AB's Debt-to-Revenue

For the Medical Devices subindustry, Bio Vitos Pharma AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio Vitos Pharma AB's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio Vitos Pharma AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bio Vitos Pharma AB's Debt-to-Revenue falls into.



Bio Vitos Pharma AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Bio Vitos Pharma AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Bio Vitos Pharma AB's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Bio Vitos Pharma AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bio Vitos Pharma AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio Vitos Pharma AB (OSTO:BIOVIT) Business Description

Traded in Other Exchanges
N/A
Address
Karlstads universitet, Biomedicin, Universitetsgatan 2, Karlstad, SWE, 651 88
Bio Vitos Pharma AB Formelry Hemcheck Sweden AB is a Sweden based medical technology company. It is developing a product addressing the issue of hemolyzed blood samples.

Bio Vitos Pharma AB (OSTO:BIOVIT) Headlines

No Headlines